BAL PHARMA
Back to Income Statement
|
BAL PHARMA Last 5 Year Revenue History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Net Sales | ₹303 Cr | ₹339 Cr | ₹304 Cr | ₹281 Cr | ₹251 Cr |
What is the latest Revenue of BAL PHARMA ?
| Year | Revenue |
|---|---|
| Mar2025 | ₹303 Cr |
| Mar2024 | ₹339 Cr |
| Mar2023 | ₹304 Cr |
| Mar2022 | ₹281 Cr |
| Mar2021 | ₹251 Cr |
How is Revenue of BAL PHARMA Trending?
| Years | Revenue | % Change | |
|---|---|---|---|
| Mar2025 | ₹303 Cr | -10.65 | |
| Mar2024 | ₹339 Cr | 11.51 | |
| Mar2023 | ₹304 Cr | 8.18 | |
| Mar2022 | ₹281 Cr | 12.25 | |
| Mar2021 | ₹251 Cr | - | |
Compare Revenue of peers of BAL PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| BAL PHARMA | ₹132.9 Cr | -4% | -9.8% | -18.5% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹446,792.0 Cr | 1.4% | 1.2% | 13.8% | Stock Analytics | |
| DIVIS LABORATORIES | ₹178,152.0 Cr | -0.5% | -0.6% | 4% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹152,915.0 Cr | 2.1% | 1.5% | 42.2% | Stock Analytics | |
| CIPLA | ₹116,354.0 Cr | 6.4% | 1.6% | -3.1% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹112,681.0 Cr | 6.2% | 1.6% | 0.2% | Stock Analytics | |
BAL PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| BAL PHARMA | -4% |
-9.8% |
-18.5% |
| SENSEX | -0.4% |
0.8% |
-5.3% |
You may also like the below Video Courses